首页> 美国卫生研究院文献>Diabetology Metabolic Syndrome >Effect of combination treatment of S–amlodipine with peroxisome proliferator-activated receptor agonists on metabolic and cardiovascular parameters in Zucker fa/fa rats
【2h】

Effect of combination treatment of S–amlodipine with peroxisome proliferator-activated receptor agonists on metabolic and cardiovascular parameters in Zucker fa/fa rats

机译:S-氨氯地平与过氧化物酶体增殖物激活受体激动剂联合治疗对Zucker fa / fa大鼠代谢和心血管指标的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundType 2 diabetes is a complex metabolic disorder characterized by hyperglycemia, impaired glucose tolerance and insulin resistance associated with dyslipidemia and hypertension. The available drugs are not sufficiently efficacious in reducing cardiovascular risk and restoring normal glucose metabolism associated with type 2 diabetes as a mono- or a combination therapy. The present study examined the combined effects of an antihypertensive (S-Amlodipine) and an insulin-sensitizing agent, peroxisome proliferator-activated receptor (PPAR) agonists (Pioglitazone and Ragaglitazar), on cardiovascular risk factors in aged diabetic and insulin-resistant Zucker fa/fa rats.
机译:背景2型糖尿病是一种复杂的代谢紊乱,其特征为高血糖,糖耐量降低和与血脂异常和高血压相关的胰岛素抵抗。现有的药物作为单一疗法或联合疗法,在降低心血管疾病风险和恢复与2型糖尿病相关的正常葡萄糖代谢方面不够有效。本研究研究了抗高血压药(S-氨氯地平)和胰岛素增敏剂,过氧化物酶体增殖物激活受体(PPAR)激动剂(吡格列酮和Ragaglitazar)对老年糖尿病和胰岛素抵抗性Zucker fa的心血管危险因素的联合作用/ fa大鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号